DV 601

Drug Profile

DV 601

Alternative Names: DV-601; HBV therapy - Dynavax; Therapeutic hepatitis B vaccine (DV-601) - Dynavax; Theravax programme - Dynavax

Latest Information Update: 27 Aug 2014

Price : $50

At a glance

  • Originator Rhein Biotech
  • Developer Dynavax Technologies
  • Class Hepatitis B vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Hepatitis B

Most Recent Events

  • 16 Oct 2013 No development reported - Phase-I for Hepatitis B (combination therapy) in Poland (Parenteral)
  • 16 Oct 2013 No development reported - Phase-I for Hepatitis B in Germany (Parenteral)
  • 29 Dec 2010 DV 601 is still in phase Ib trials for Hepatitis B infection in Poland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top